Brokerages Anticipate Zymeworks Inc (ZYME) Will Announce Earnings of -$0.62 Per Share
Wall Street analysts expect that Zymeworks Inc (NYSE:ZYME) will report earnings of ($0.62) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Zymeworks’ earnings, with the highest EPS estimate coming in at ($0.60) and the lowest estimate coming in at ($0.63). The firm is expected to announce its next earnings report on Wednesday, February 14th.
On average, analysts expect that Zymeworks will report full-year earnings of ($3.09) per share for the current year, with EPS estimates ranging from ($3.13) to ($3.04). For the next financial year, analysts forecast that the firm will post earnings of ($2.60) per share, with EPS estimates ranging from ($2.71) to ($2.48). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Zymeworks.
Zymeworks (NYSE:ZYME) last posted its earnings results on Wednesday, November 8th. The company reported ($0.65) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.09. Zymeworks had a negative return on equity of 117.85% and a negative net margin of 1,387.89%.
Shares of Zymeworks (ZYME) opened at $9.49 on Tuesday. Zymeworks has a fifty-two week low of $6.25 and a fifty-two week high of $14.25.
An institutional investor recently bought a new position in Zymeworks stock. OxFORD Asset Management LLP bought a new stake in Zymeworks Inc (NYSE:ZYME) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 18,467 shares of the company’s stock, valued at approximately $154,000. OxFORD Asset Management LLP owned about 0.07% of Zymeworks as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 7.20% of the company’s stock.
Zymeworks Company Profile
Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.